Under MDR Article 61 and Annex XIV, every medical device must be supported by an ongoing clinical evaluation. Manufacturers are expected to plan, gather and continuously appraise clinical evidence demonstrating safety, performance and an acceptable benefit-risk profile.
A clinical evaluation therefore runs through five stages:
1. Scoping. Define the device, intended purpose, indications, target population, clinical claims and the GSPRs requiring clinical support.
2. Planning (CEP). Establish the clinical evaluation strategy, methodology, relevant data sources, outcome parameters, acceptance criteria and predefined appraisal methods in the Clinical Evaluation Plan (CEP).
3. Identification of clinical data. Systematically identify relevant literature and gather clinical investigation, pre-clinical, PMS, PMCF and other relevant clinical data.
4. Appraisal. Critically evaluate the relevance, quality and contribution of the available evidence using predefined criteria and standardized appraisal methods.
5. Analysis and reporting (CER). Bring the evidence together, evaluate the benefit-risk profile and document the conclusions of the clinical evaluation in the Clinical Evaluation Report (CER).
The important point is that these are not isolated regulatory tasks. Each stage needs to logically support the next.
Download our whitepaper where we explain MDR expectations, show how to create consistency in a robust clinical evaluation and explain how to incorporate AI-supported tools in selected activities within the clinical evaluation workflow.
